A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288

Simply Wall St.01-10

Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602396695?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-10 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602396695","market":"us","top_or_hot":-1,"title":"A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288","media":"Simply Wall St.","content":"<div>\n<p>Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af","article_id":"2602396695","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602396695","pubTimestamp":1768054675,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies.\nSee our latest analysis for Ascentage Pharma Group International.\nThe FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","LU1923622291.USD":"Natixis Thematics Safety R/A USD","BK1161":"生物科技","APG":"APi Group Corp","BK4129":"建筑与工程","LU2125909759.SGD":"Natixis Thematics Safety H-R/A SGD","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","IND":"Xtrackers Nifty 500 India ETF","06855":"亚盛医药-B"},"translate_title":"APG-3288获得FDA IND批准后亚盛医药集团国际的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APG":1.5,"06855":0.9,"IND":1.5},"content_text":"Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies. See our latest analysis for Ascentage Pharma Group International. The FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%, suggesting short term momentum after a 90-day share price return decline of 24.21%. The 1-year total shareholder return of 38.41% and 3-year total shareholder return of 85.96% point to a stronger longer term record. If this kind of biotech progress has your attention, it could be a good moment to scan other healthcare stocks that might fit your watchlist. Use it to spot ideas you have not looked at yet. With the stock at HK$54.95 and flagged as having a low value score alongside a large intrinsic discount, investors might wonder: is there still mispricing here, or are markets already baking in future growth potential? AdvertisementMost Popular Narrative: 40.8% Undervalued Against the last close of HK$54.95, the most followed narrative sees fair value much higher, built on an aggressive earnings and margin trajectory.  Analysts expect earnings to reach CN¥50.7 million (and earnings per share of CN¥0.12) by about August 2028, up from CN¥-405.4 million today. However, there is a considerable amount of disagreement amongst the analysts, with the most bullish expecting CN¥905 million in earnings and the most bearish expecting CN¥-528.9 million.  Read the complete narrative. Curious how revenue, margins and a future profit multiple come together to justify this valuation gap? The core drivers sit in a tight set of bold projections. Want to see exactly which assumptions carry the most weight here? Result: Fair Value of $92.81 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on key uncertainties, including heavy dependence on Olverembatinib in China and high R&D spend that could delay any path to sustainable profitability. Find out about the key risks to this Ascentage Pharma Group International narrative. Another View: Price To Sales Sends A Different Signal Our DCF model points to a large discount to fair value, yet the P/S ratio tells a very different story. Ascentage Pharma trades on a P/S of 46.4x, far above the Hong Kong Biotechs industry at 13.9x, the peer average at 14x, and our fair ratio of 14.9x. That kind of gap can indicate meaningful valuation risk if expectations around growth or margins slip even slightly. This raises the question of which signal is more reliable. See what the numbers say about this price — find out in our valuation breakdown. SEHK:6855 P/S Ratio as at Jan 2026 Build Your Own Ascentage Pharma Group International Narrative If you are not convinced by these views or simply prefer to weigh the numbers yourself, you can build a fresh take in just a few minutes: Do it your way A great starting point for your Ascentage Pharma Group International research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Ready for more investment ideas? If Ascentage Pharma has sharpened your focus, do not stop here, the right mix of new ideas could shift how you think about opportunities across your portfolio.  Spot potential value gaps fast by scanning these 879 undervalued stocks based on cash flows that may be trading below what their cash flows suggest. Ride powerful technology shifts by focusing on these 28 AI penny stocks that tie artificial intelligence to real business models. Hunt for income today with these 12 dividend stocks with yields > 3% that offer yields above 3% plus supporting fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602396695","isCrawlerRequest":true}